Business Description
PT Kalbe Farma Tbk
ISIN : ID1000125107
Share Class Description:
FRA:LCLA: Ordinary SharesTotal Employee Number:
12,895Description
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.94 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 147.33 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 6.73 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.6 | |||||
3-Year EBITDA Growth Rate | 3.1 | |||||
3-Year EPS without NRI Growth Rate | 3 | |||||
3-Year FCF Growth Rate | 84.3 | |||||
3-Year Book Growth Rate | 5.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.79 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.95 | |||||
9-Day RSI | 46.2 | |||||
14-Day RSI | 47.2 | |||||
3-1 Month Momentum % | -40.74 | |||||
6-1 Month Momentum % | 4.92 | |||||
12-1 Month Momentum % | -55.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.56 | |||||
Quick Ratio | 2.23 | |||||
Cash Ratio | 0.81 | |||||
Days Inventory | 114.2 | |||||
Days Sales Outstanding | 58.99 | |||||
Days Payable | 38.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.27 | |||||
Dividend Payout Ratio | 0.5 | |||||
3-Year Dividend Growth Rate | 0.9 | |||||
Forward Dividend Yield % | 3.27 | |||||
5-Year Yield-on-Cost % | 2.78 | |||||
3-Year Average Share Buyback Ratio | 0.7 | |||||
Shareholder Yield % | 4.64 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.55 | |||||
Operating Margin % | 12.39 | |||||
Net Margin % | 9.99 | |||||
EBITDA Margin % | 14.09 | |||||
FCF Margin % | 6.56 | |||||
OCF Margin % | 8.84 | |||||
ROE % | 15.52 | |||||
ROA % | 11.83 | |||||
ROIC % | 15.74 | |||||
3-Year ROIIC % | 17.28 | |||||
ROC (Joel Greenblatt) % | 26.41 | |||||
ROCE % | 18.47 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 6.33 | |||||
Forward PE Ratio | 11.75 | |||||
PE Ratio without NRI | 6.32 | |||||
Shiller PE Ratio | 11.13 | |||||
Price-to-Owner-Earnings | 10.73 | |||||
PEG Ratio | 1.66 | |||||
PS Ratio | 0.63 | |||||
PB Ratio | 0.94 | |||||
Price-to-Tangible-Book | 1.5 | |||||
Price-to-Free-Cash-Flow | 9.7 | |||||
Price-to-Operating-Cash-Flow | 7.19 | |||||
EV-to-EBIT | 6.71 | |||||
EV-to-Forward-EBIT | 5.97 | |||||
EV-to-EBITDA | 6.23 | |||||
EV-to-Forward-EBITDA | 5.74 | |||||
EV-to-Revenue | 0.88 | |||||
EV-to-Forward-Revenue | 0.79 | |||||
EV-to-FCF | 13.93 | |||||
Price-to-GF-Value | 0.43 | |||||
Price-to-Projected-FCF | 0.75 | |||||
Price-to-DCF (Earnings Based) | 0.6 | |||||
Price-to-DCF (FCF Based) | 0.75 | |||||
Price-to-Median-PS-Value | 0.3 | |||||
Price-to-Graham-Number | 0.75 | |||||
| Price-to-Net-Current-Asset-Value | 3 | |||||
Earnings Yield (Greenblatt) % | 14.91 | |||||
FCF Yield % | 6.84 | |||||
Forward Rate of Return (Yacktman) % | 8.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PT Kalbe Farma Tbk Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,872.302 | ||
| EPS (TTM) (€) | 0.004 | ||
| Beta | 0.7215 | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 99.94 | ||
| 14-Day RSI | 47.2 | ||
| 14-Day ATR (€) | 0.009501 | ||
| 20-Day SMA (€) | 0.033175 | ||
| 12-1 Month Momentum % | -55.86 | ||
| 52-Week Range (€) | 0.0235 - 0.084 | ||
| Shares Outstanding (Mil) | 45,248.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PT Kalbe Farma Tbk Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PT Kalbe Farma Tbk Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| IDR 20.000000 Cash Dividend | 2026-06-04 | 0.03 (+5.88%) | ||
| IDR 36.000000 Cash Dividend | 2025-06-04 | 0.08 (+1.35%) | ||
| 5:1 Stock Split | 2012-10-08 | 0.07 (+0.00%) |
Show
Entries
PT Kalbe Farma Tbk Frequently Asked Questions
What is PT Kalbe Farma Tbk(FRA:LCLA)'s stock price today?
The current price of FRA:LCLA is €0.03. The 52 week high of FRA:LCLA is €0.08 and 52 week low is €0.02.
When is next earnings date of PT Kalbe Farma Tbk(FRA:LCLA)?
The next earnings date of PT Kalbe Farma Tbk(FRA:LCLA) is .
Does PT Kalbe Farma Tbk(FRA:LCLA) pay dividends? If so, how much?
The Dividend Yield %  of PT Kalbe Farma Tbk(FRA:LCLA) is 3.27% (As of Today), Highest Dividend Payout Ratio of PT Kalbe Farma Tbk(FRA:LCLA) was 0.64. The lowest was 0.37. And the median was 0.46. The  Forward Dividend Yield % of PT Kalbe Farma Tbk(FRA:LCLA) is 3.27%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on PT Kalbe Farma Tbk
No articles.